SCHEMBL3889336

SCHEMBL3889336

Fc1cc(F)cc(-c2nc(N3CCOCC3)nc(N3CCN(c4ccccn4)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.48
TSHR P16473 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
PIK3CA P42336 7/20 0.47
MTOR P42345 6/20 0.47
PIK3R1 P27986 4/20 0.47
PIK3CG P48736 2/20 0.46
DRD4 P21917 1/20 0.46
PIK3CB P42338 1/20 0.46
HRH4 Q9H3N8 1/20 0.45
MAPK1 P28482 1/20 0.45
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879427 0.91 PIK3CA (0.52) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3887621 0.89 PIK3CA (0.58) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL13761287 0.86 HTT (0.61) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3877695 0.86 PIK3CA (0.48) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3879447 0.86 HSD17B10 (0.54) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3881099 0.85 NPSR1 (0.53) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3876007 0.83 MEN1 (0.51) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3878479 0.83 BCHE (0.57) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL3885540 0.83 BCHE (0.49) HSD17B10HPGDALDH1A1KDM4EMAPT
SCHEMBL1124002 0.82 HPGD (0.60) HSD17B10HPGDALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US claimed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG HSD17B10 3040/4885HPGD 952/4885ALDH1A1 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.